WTR Healthcare Happenings

Joe Brunetto
  • 5.0 (2)
  • INVESTING
  • UPDATED WEEKLY

WTR Healthcare Happenings is a weekly conversation with healthcare executives, medical experts, and investors on recent clinical data or industry-driving events in healthcare.

  1. 6H AGO

    CEO Dr. Lior Shaltiel Discusses How NurExone Biologic Stands Out As an Early-Clinical Stage Biotech

    In this episode of WTR Healthcare Happenings, host Tim Gerdeman and WTR’s Robert Sassoon speak with Dr. Lior Shaltiel, CEO of NuroExone Biologic (OTCQB: NRXBF/TSXV: NRX), an early-stage regenerative therapy developer.  The conversation centers on NurExone’ lead product, ExoPTEN, a therapeutic platform that combines exosomes with siRNA to promote nerve regeneration in multi-billion dollar markets like spinal cord and optic nerve injury. Dr. Shaltiel outlines the company’s strong preclinical evidence, its de-risked characteristics bolstered by Orphan Drug Designation in both the US and Europe, and the company's multi-layered patent strategy. He also highlights NuRexone' unique US-based manufacturing model designed to generate revenue within the next year as they move toward clinical trials.

    12 min

  2. FEB 4

    Taking Aim at Norovirus; Cocrystal Pharma's (COCP) Clinical Antiviral Opportunity

    In this episode of the WTR Healthcare Happenings Podcast, Tim Gerdeman and Robert Sassoon speak with Jim Martin, Co‑CEO and CFO of Cocrystal Pharma (NASDAQ: COCP). Martin explains the company’s Nobel Laureate‑developed drug discovery platform, which uses high-resolution crystallography to target viral regions resistant to mutation, enabling broad‑spectrum antivirals. The discussion highlights Cocrystal’s lead candidate, CDI‑988, a dual‑indication antiviral for coronaviruses and noroviruses, with a particular focus on advancing the norovirus program due to high global unmet need. Martin outlines the ongoing human challenge norovirus study at Emory University, CDI‑988’s potential as therapy and prophylactic, and growing U.S. government and military interest. The episode also highlights the company' upcoming milestones, including mid‑2026 top-line data for the CDI-988 human challenge study, and an overview of its broader pipeline, including influenza A and B programs. Best,

    27 min

  3. JAN 28

    How Entropy Neurodynamics (ASX: ENP) Is Shaping Psychedelic‑Assisted Therapy: Psilocin Programs, Binge Eating Disorder, and EEG Biomarker

    In this episode of the WTR Healthcare Happenings Podcast, host Tim Gerdeman and healthcare analyst Robert Sassoon are joined by Dr. Jim Gilligan, President and Chief Science Officer of Entropy Neurodynamics (ASX: ENP), formerly Tryptamine Therapeutics. Dr. Gilligan explains the motivation behind the company’s rebrand and its decision to prioritize three core therapeutic targets: Binge Eating Disorder, Fibromyalgia, and Irritable Bowel Syndrome/abdominal pain. Although Entropy has reported positive Phase 2a results using oral psilocybin across these indications, Dr. Gilligan outlines why the company is shifting its strategy toward developing proprietary IV‑delivered psilocin formulations combined with psychotherapy, beginning with binge eating disorder. The discussion also covers Entropy’s work on real‑time EEG and brain entropy as a potential biomarker, the company’s financing,  regulatory roadmap, and longer‑term expansion opportunities in areas such as PTSD.

    28 min

  4. JAN 22

    Anixa' (ANIX) T-Cell Innovations Demonstrate Early Breakthrough Potential in Solid Tumors

    In this special Flashcast episode of the WTR Healthcare Happenings podcast, Tim Gerdeman sits down with WTR Healthcare analyst Robert Sassoon to discuss his Initiation of Coverage Report on Anixa Biosciences. Their conversation explores Anixa’s two clinical‑stage programs—one, an innovative CAR‑T cell therapy for terminal ovarian cancer patients, and the other, a breast cancer vaccine designed for both treatment and prevention. They review Phase 1 results, upcoming 2026 milestones, and how Anixa differentiates itself through both its scientific platforms and disciplined financial management.

    13 min

  5. JAN 16

    The lure of the NASDAQ for Biotechs

    In this special Flashcast episode of the WTR Healthcare Happenings podcast, Tim Gerdeman and WTR Healthcare analyst Robert Sassoon break down why more than 90% of biotech companies listed on a U.S. exchange choose NASDAQ over the NYSE.

    7 min

  6. JAN 8

    Redefining Cancer Treatment: Calidi Biotherapeutics’ Approach to Enable Systemic Oncolytic Virotherapy for Metastatic Disease

    In this episode of WTR Healthcare Happenings, host Tim Gerdeman and analyst Robert Sassoon speak with Eric Poma PhD, CEO of Calidi Biotherapeutics Inc (NYSE American: CLDI).  The discussion focuses on how Calidi is solving the "delivery problem" in cancer treatment, and specifically how to transport cancer-killing oncolytic viruses systemically through the bloodstream without the body’s immune system neutralizing them before they reach the tumor.

    19 min

  7. 12/23/2025

    Co-Diagnostic' Technology to Deliver Accessible, High-Fidelity Gold Standard PCR Testing Like No Other

    In this episode of WTR Healthcare Happenings, host Tim Gerdeman and analyst Robert Sassoon speak with Dwight Egan, CEO of Co-Diagnostics Inc. (NASDAQ: CODX), about the company’s evolution from a pandemic-era PCR testing provider to a diversified molecular diagnostics leader. In our discussion, Egan highlights the Co-DX PCR Pro, a portable, cost-effective device that delivers gold-standard PCR testing outside the lab and explains how its patented Co-Primer multiplexing technology sets it apart from competitors. Our conversation also covers Co-Diagnostics’ “razor-and-blade” business model, its pipeline of testing capabilities targeting high-impact infectious diseases, the role of AI in manufacturing and diagnostic optimization, and the commercial strategies needed to achieve long-term financial success.

    20 min

  8. 12/19/2025

    CEO Jagi Gill on How Apyron' Innovative Neurostimulation Solution Breaks the Chronic Pain Barrier

    In this episode of WTR Healthcare Happenings,  host Tim Gerdeman and analyst Robert Sassoon talk with Apyron CEO Jagi Gill about the company's innovative neurostimulation technology for chronic pain, an all too prevalent affliction affecting millions of people.  Gill explains why Apyron’s patient-focused approach stands out, and outlines the market opportunity and commercialization strategy.

    22 min
See All (39)

Ratings & Reviews

5
out of 5
2 Ratings

About

WTR Healthcare Happenings is a weekly conversation with healthcare executives, medical experts, and investors on recent clinical data or industry-driving events in healthcare.

Information

  • Creator
    Joe Brunetto
  • Years Active
    2025 - 2026
  • Episodes
    39
  • Rating
    Clean
  • Copyright
    © 2026 WTR Healthcare Happenings
  • Show Website
    WTR Healthcare Happenings